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ABSTRACT

The subject of this paper is the relationship between glucose6-phosphate dehydrogenase (G6PD) deficiency and bacterial infection.
The relevant literature is reviewed in two parts.

First, major bio¬

chemical and clinical aspects of G6PD deficiency are discussed.

The

second part covers neutrophil function and dysfunction; leukocyte G6PD
and the implications of its deficiency are placed within the context
of other neutrophil disorders.
comprised our study group.

A hospitalized Iranian population

When we compared the rates of G6PD deficiency

in infected and non-infected patients, the difference reached statistical
significance under certain circumstances (.05 > p >

.01).

Our data

also showed the G6PD deficient infected patients to be significantly
younger than the G6PD normal infected patients

(.005 > p >

.001).

This

is consistent with the hypothesis that G6PD deficient patients, once
infected, have a more severe clinical course.

We conclude that there

are significant interactions between G6PD deficiency and bacterial
infection, although their exact nature remains to be defined.

Mechanisms

which would explain an association between these two conditions are
discussed.
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Definitions and History
Glucose-6-phosphate dehydrogenase (G6PD),

the first enzyme in

the pentose phosphate pathway, catalyzes the conversion of glucose-6phosphate to 6-phosphogluconolactone while reducing NADP to NADPH
[Figure l].

The major practical importance of G6PD lies in its role

in the red blood cell, where its deficiency can cause hemolytic anemia.
Most commonly,

the anemia is episodic and is related to one of a number

of agents, but occasionally a chronic hemolytic anemia occurs.

Although

the former entity has been known for thousands of years, it was only
recently that the link between G6PD deficiency and hemolytic anemia was
established.

In 1926, plasmoquin, an 8-amirioquinoline compound, was

first used in treating syphilitics who had been inoculated with malaria;
shortly thereafter, a series of reports appeared describing hemolytic
anemia with administration of the drug [1].

Little progress was made

in determining the etiology of the condition until 1950, when investi¬
gators received a new research tool in the form of primaquine, a compound
related to but therapeutically more effective than plasmoquin.
Dern et al.

In 1954

[2], utilizing cross-transfusions between normal and

primaquine-sensitive individuals, demonstrated that the basic abnormality
was in the red blood cell.

Other investigators found that the hemolytic

susceptibility was restricted to the older erythrocytes and, since at
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least some metabolic processes were known to decrease with aging,
attention was directed towards a metabolic disorder [1],
Carson and his collaborators

In 1965,

[3] reported a decreased G6PD level in

the erythrocytes of affected individuals.

Mechanisms of Hemolysis
Although it was soon generally accepted that the G6PD deficiency
and hemolytic anemia were related, detailed understanding of the hemo¬
lytic mechanism was and still is lacking.

An outline of events as they

are known requires a brief digression into certain aspects of erythrocyte
biochemistry.
As mentioned before, G6PD is one of the enzymes of the hexose
monophosphate shunt (HMP)

[Figure l].

This pathway is very important

to the red blood cell, even though it metabolizes a much smaller quantity
of glucose than the Embden-Meyerhof pathway.

The reduction of NADP to

NADPH and the production of the nucleotide precursor ribose-5-phosphate
take place via the HMP.

The latter can also be formed by other means;

in contrast, NADPH in red cells is supplied entirely by the HMS.

A

source of NADPH is critical because it acts as the coenzyme for the
conversion of oxidized glutathione (GSSG) to reduced glutathione (GSI1) .
The GSH prevents the oxidation of sulfhydryl groups of proteins such
as hemoglobin, usually because GSH itself is instead oxidized to GSSG.
In cases where the oxidant is
H^O [4],

GSH acts by reducing the H,,G^ to

A second important role of NADPH is to provide electrons for

reduction and cleavage of GSK-hemoglobin complexes, which would otherwise
be liable to precipitate.
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It is believed that infections, fava beans, and other stimuli
induce hemolysis by causing the production of various oxidizing substances
such as

or ot^er unstable radicals.

have oxidizing capacity.

Drugs themselves can also

In the normal person,

these substances can

be handled by the production of NADPH from the HMS, but G6PD deficiency
blocks this pathway.

Consequently,

the erythrocyte proteins, including

hemoglobin, are not protected from oxidation.
denature and precipitate as Heinz bodies,
the cell membranes,

Oxidized hemoglobin can

and by binding to and damaging

the Heinz bodies increase cell susceptibility to

removal by the reticuloendothelial system [1,5].
Baehner £t al.

[6] have made a more specific proposal regarding

the mechanism of hemolysis during infection; they suggest that HpC^
produced by phagocytizing leukocytes could serve as a partial source
of the oxidant stress.

Their hypothesis was supported by experiments

in which phagocytizing leukocytes caused a fall in GSII in neighboring
G6PD deficient red blood cells, a result associated with increased
destruction of these cells in the liver and spleen.

The effect was

not present with normal erythrocytes, nor with separation of the G6PD
deficient cells from the leukocytes.

Pyrimidine aglycons have been

implicated as the offending agent in favism [7],

and naturally occurring

substances such as ascorbate, pyruvate, and cysteine in "spontaneous"
hemolysis [5].

G6PD Variants
During the course of these and other investigations,

it became

clear that G6PD deficiency varied enormously biochemically and clinically.
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Over 80 variants have now been described in the 100 million or so people
with the condition [8], and doubtless more remain to be found.

Only

a few of the major variants will be discussed here; complete compilations
are available in the literature [9,30].
The normal G6PI) enzyme, known as type B, has a molecular weight
of 190,000 to 240,000 and has 3 to 6 similar or identical subunits,
although the functioning enzyme is probably dimeric [1].
properties,

The biochemical

including substrate affinity, thermostability, optimal pH,

and electrophoretic characteristics,

are well known [Table 1],

One of

the most common variants, called type A because it migrates faster than
type B, is present in approximately 30 percent of American black males
[5].

With the use of trypsin digests,

by only a single amino acid

[11].

it was found to differ from type B

Type A has normal activity and so has

little clinical importance, in contrast to Type A

(which receives its

name because it migrates wit3t Type A, but has decreased activity).
About 11 percent of American black males have Type A
exists in varying frequencies throughout Africa.
of each A

[5] and the gene

The catalytic activity

enzyme molecule, is close to normal, but there is a fall in

the total number of molecules [1], and the decrease in activity between
young and old cells is more marked than in normal cells [12,13].

Overall,

the activity in the blood is usually 5-15 percent of normal [5]; very
rarely, activity can be absent [14].

Affected individuals are generally

asymptomatic except under conditions of stress, such as with certain
drugs or infection [Table 2].
older cells,

Because G6PD activity is low only in

the hemolysis tends to be mild and self-limited; a typical

..

0

'
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time course involves an onset 1 to 3 days after the inciting agent has
been introduced, with recovery beginning in A to 6 days [5].
A more severe form of G6PD deficiency is found in

area, including Sardinia, Italy, Greece, Iran, Rumania,
perhaps some areas in the Far East [15].
Mediterranean,

the Mediterranean
Israel, and

It is possible that G6PD

as it is known, represents a heterogeneous group [11,16,

17,18] but the major biochemical characteristics listed in Table 1 are
constant.

The frequency of the gene ranges from less than 0.1 percent

in Northern Europe to greater than 50 percent of Kurdish Jewish males
[5].

The quantity of enzyme is reduced in very young red blood cells,

and their catalytic efficacy is also lower [1].
are affected,

Because all erythrocytes

the G6PD activity of whole blood tends to be less than

1 percent, and the hemolytic episodes are often more severe and not
self-limiting.

The list of precipitating agents is similar to, but not

identical with,

that for G6PD A ; for example, chloramphenicol causes

hemolysis in G6PD Mediterranean but not G6PD A

[Table 2].

Fava beans,

which can lead to an extremely rapid and severe hemolysis, also appear
to affect mainly Caucasians

[8].

Another factor may also be involved,

since only some G6PD Mediterranean patients are affected by the fava
beans.
A host of other G6PD variants have been described, ranging from
G6PD Canton, similar in its properties to G6PD Mediterranean [15], G6PD
Oklahoma, with a tremendous deterioration in activity with aging [19]
and G6PD Hektoen, with increased activity [5].

The clinical manifesta¬

tions depend on the characteristics of the enzyme; patients can be

6

asymptomatic, have mild or severe disease resembling that described
above, or rarely, have a chronic nonspherocytic anemia.

Seen with some

of the rarer types of G6PD deficiency, as well as occasionally in G6PD
Mediterranean,

the degree of shortened erythrocyte lifespan is generally

mild [5],

Leukocyte G6PD
G6PD deficiency is not necessarily limited to the red blood cells
and articles have appeared describing decreased levels in leukocytes,
lens tissue, kidney, adrenal tissue, platelets, saliva, liver and other
tissues [1];

most of these studies were in Caucasians

[8,20].

A

complete analysis of these reports is not feasible here, and only the
leukocyte levels will be discussed in some detail.

While most people

believe that the leukocyte and erythrocyte enzymes are the same [1],
some investigators have claimed differences
not been definitively settled.

[1,19] and the issue has

One published report even showed separate

inheritance of the two defects, but the measurement techniques described
are open to question [21].

Moreover,

firmed by other researchers.

the findings have not been con¬

In any case, several different studies

have demonstrated lowered leukocyte levels in association with some
types of erythrocyte G6PD deficiency.

Marks and Gross

[12] reported

that Caucasian, but not black, males with severe erythrocyte G6PD
deficiency (less than 4.5 standard deviations below control values)
have a leukocyte G6PD level approximately one third that of controls.
A similar study carried out by Ramot et jal.
25 percent of normal activity.

[22] showed leukocytes with

Affected Chinese males have also been
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found to have decreased leukocyte G6PD levels

[23],

The potential

functional significance of lowered leukocyte G6PD levels to the anti¬
microbial activities of these cells will be discussed below.

Mode of Inheritance
The mode of inheritance of G6PD deficiency is well known to be
X-linked.

It was established by inheritance patterns, and with linkage

studies of other traits such as color blindness and hemophilia A.
The study of a patient with Turner's syndrome and fully expressed
G6PD deficiency helped to rule out a sex-influenced process
G6PD deficiency was,

[7].

in fact, instrumental in confirmation of the

Lyon hypothesis; Beutler et_ a_l.

[24] studied females heterozygous for

the trait and found two distinct populations of cells, rather than one
with intermediate activity.

It is a useful cell marker in other systems,

for example the study of blood cell precursor development

[25] and

Down's syndrome [26].

G6PD Deficiency and Associated Conditions
In the short time that it has been known, G6PD deficiency has
been associated with a number of other pathological processes.

Its

relationship to bacterial infection is complex, and leukocyte G6PD
levels may well play a role in host defenses.

This subject will be

addressed in the following two sections of this paper; here, only a
brief review of specific associated conditions, infectious and noninfectious, is presented.
One area of great controversy concerns whether G6PD deficiency
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might have a selective advantage in some circumstances.

The fact that

it is so common, and that the distribution to some extent parallels
that of malaria, has led to the hypothesis that G6PD deficiency might
confer a degree of protection against malaria.

Support for this

idea has been gathered in a series of experiments, most of which used
G6PD A

and Plasmodium falciparum;

these experiments demonstrated

decreased parasitization of the G6PD deficient red blood cells as
compared to normal [27,28].
proposed by Kosover [29]:

An explanation for this protection was
the increased level of GSSG, a substance

known to inhibit protein synthesis in rabbits, could act to retard
parasite proliferation.

These theories leave many points unexplained,

including the fact that G6PD deficiency is so frequent and severe in
areas where there is a fairly high selective disadvantage due to the
popularity of fava beans.

Huheey and Martin [30] suggested that

favism may augment G6PD deficiency's protective effect against malaria,
but this remains pure speculation.

They also point out that G6PD

Mediterranean may be particularly effective in combating P_. vivax,
which is more important than P_.

falciparum in Mediterranean areas.

Their reasoning is that P. vivax has more exoerythrocytic stages than
P_. falciparum, and in G6PD Mediterranean many body tissues, including
the liver, are G6PD deficient.

Finally, as Carson and Fischer [7]

have noted, there are other diseases, such as plague, which have a
similar distribution and might also have played a selective role.
G6PD deficiency is a well known cause of neonatal jaundice, and
in some parts of the world may be the most common one [19].

The process

.
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seems to affect Caucasian,
Valaes e_t al.

Indian, and Oriental infants [8,31,32].

[33] studied groups of Greek newborns, confirming the link

between G6PD deficiency and neonatal jaundice while raising additional,
complicating issues.

They found evidence for another icterogenic factor

which accentuated the jaundice in normal and deficient patients;

they

also found that the degree of hyperbilirubinemia and anemia were not
always parallel, as one might expect in a hemolytic state.
Meloni et al.

Recently,

[34], discovering that barbiturates were therapeutically

effective, postulated that transiently impaired liver function could
also be partly responsible for the jaundice.

An increased incidence

and severity of jaundice has also been noted in black and Caucasian
hepatitis patients with G6PD deficiency [35,36,37],

Doubtless this

is partly due to hemolysis resulting from the oxidative stress of
infection, but similar to neonatal jaundice, the evidence for hemolysis
was not always entirely convincing, and other factors were believed
to contribute.

Jaundice has been associated with lobar pneumonia in

African G6PD patients

[38,39] and liver biopsies have shown changes

consistent with cholestasis [40].

G6PD deficiency has been reported

to predispose to typhoid in Ghana [41] and Thailand [42], but both
studies could be questioned on grounds of bias in patient selection.
A small study in India linked leprosy and G6PD deficiency [43], while
TB was shown not to be related to G6PD deficiency in the Far East [44],
Regarding non-infectious diseases, several investigators have
produced population studies showing an inverse relationship between
G6PD deficiency and malignancy [45,46,47,48], but the study and control
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groups differ in a number of ways and many other etiologies are equally
or more plausible.

Beaconsfield [45] did have an interesting suggestion

of why G6PD deficiency and cancer might be related:

lack of G6PD by

depressing the pentose phosphate pathway interferes with pentose sugar
and nucleic acid production and impedes rapid growth.

More recently,

Eaton [49] noted that catalase inactivation stimulates the phosphate
shunt and some investigators have found decreased liver catalase with
hepatomas, reinforcing the idea that the pentose phosphate pathway may
be an important limiting factor in neoplastic (and possibly malarial)
processes.

Other diseases described as being related to G6PD deficiency

include thalassemia [50], cataracts [51], regional enteritis, and
granulomatous colitis [52,53], but the data is tenuous.

Finally,

a considerable amount has been written on the relationship of Hemo¬
globin S and G6PD deficiency [54,55,56,57,58],
is not yet totally resolved,

While the controversy

the prevailing opinion is that the genes

are common in the same populations, but that the presence of one docs
not appreciably alter the clinical course of the other.

II

NORMAL NEUTROPHIL FUNCTION [5,8,59]

Production and Delivery
Neutrophils,

the chief phagocytic cells in the blood, make up

the myeloid series together with eosinophils and basophils.

The first

morphologic stage in their development is the myeloblast; whether there
are distinct myeloblasts for each of the three lines of the myeloid
series is unknown.

Morphologically, myeloblasts are characterized by

large nuclei with two to five nucleoli and even, diffuse chromatin,
while the small quantity of basophilic cytoplasm contains numerous
mitochondria and no granules.

Myeloblasts give rise to promyelocytes,

which can be distinguished by the increasingly prominent endoplasmic
reticulum and, more importantly, the appearance of primary,
granules.

azurophilic

These are formed on the concave surface of the Golgi body

and are rounded or elongated, with crystalline contents of lysosomal
hydrolases, myeloperoxidase, cationic proteins and others.

Secondary

granules, which appear first in the myelocyte stage, are made on the
convex surface of the Golgi body and are variable in shape.

Their

homogeneous appearing contents include alkaline phosphatase and lactoferrin.

This type of secondary granule is unique to neutrophils, and

the myelocyte is thus the first stage at which differentiation of cell

11
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lines can be made.

Metamyelocytes have clearly indented nuclei lacking

nucleoli, and moderately dense, sometimes clumped nuclear chromatin.
The endoplasmic reticulum is much less prominent, as one would expect
from the decrease in protein synthesis; under normal circumstances,
metamyelocytes have probably lost their ability to divide and reproduce.
The final two stages,

the juvenile or band form and the mature poly¬

morphonuclear leukocyte are usually distinguished on the basis of their
nuclei; the former has partial separation of the nuclear lobes, while
in the latter there are only thread-like connections.

The nuclei of

mature cells have coarse, condensed chromatin, and the cytoplasm contains
both types of granules.

In accord with the fact that their main source

of energy is glycolysis,

there are large stores of glycogen but few

mitochondria.

Precise understanding of the regulation of the relative

numbers of cells in various stages of development in the marrow,

the

intravascular pool (both circulating and marginated) and the tissues
is lacking at present.

Several granulopoietic agents have been described.

Other factors which may regulate the number of cells in different body
pools include physiologic cycling (possibly at several different inter¬
vals),' heat, exercise, emotional state, infection, and drugs

[5,8].

The processes by which neutrophils are delivered to sites of
inflammation are complex.

For unknown reasons, capillary endothelium

can change in such a way as to cause local granulocyte adherence
followed by diapedesis through vessel walls

[60],

This tends to occur

in injured areas, and the white cells are further drawn to inflamed
regions by two kinds of substances:

cytotoxins, which act directly,
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including most Importantly by-products of complement activation, and
cytotaxigens, which generate cytotaxins and include lysosomes, endo¬
toxins and immunologic complexes.

These chemotactic factors do not

increase the speed at which neutrophils move, but rather influence
their direction [8].

It is known that while migrating, polymorpho¬

nuclear leukocytes develop a stiff rim of cytoplasm that contains actin
polymers and glycogen particles, and that the ability to assemble micro¬
tubules is integral to responding with directed movement.

Precise

details of the events in migration are lacking, however.

Phagocytosis:

Recognition and Ingestion

The susceptibility of many microbes to phagocytosis by neutrophils
is enhanced by the process of opsonization.

Both bacteria and poly¬

morphonuclear leukocytes, particularly immature forms, have a net
surface charge which is negative and they therefore naturally tend to
repel each other.

Opsonins are traditionally defined as agents in

serum which enhance the palatibility of particles

[60].

They consist

most importantly of heat-labile complement and heat stable antibody;
specific receptors for the Fc. fragment of IgG and for C3b may exist in
neutrophils.

Specific IgG antibody,

therefore, can bind and opsonize

directly, although in most physiological situations complement is
probably also activated.

In contrast, IgM must act via complement

fixation since it has no specific receptors.

In the absence of antibody

some bacteria themselves can activate the alternate complement pathway
[60,61].

It is possible that different bacteria require fixation of

different complement products

[62], and under some circumstances organisms
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can be taken up if there is a suitable surface against which they can
be trapped, so-called "surface phagocytosis"

[60],

In order for the

microbes to be ingested energy must be generated; as mentioned earlier,
it is produced by glycolysis and oxygen is not required.

This is

probably advantageous, in view of the often anoxic inflammatory environ¬
ment.

During the act of attachment the hyaline ectoplasm, the outer

cytoplasmic rim, forms filopodia which surround the particle.

With

phagocytosis the cellular membrane surrounding the particle is internalized,
forming a phagosome whose walls are comprised of former plasma membrane.

Killing and Digestion
During ingestion, lysosomes fuse with the phagosomal membrane
and discharge their contents into the vacuole; most likely the secondary
granules fuse shortly before the primary.

This process is known as

lysosomal degranulation and the enzymes released mediate the oxygen
independent microbicidal system.

They have a variety of partially

understood effects; for example, the hydrolases are believed to digest
the bacteria and to prevent bacterial multiplication,
iron,

lactoferrin binds

a necessary growth factor, and myeloperoxidase has a complicated

bactericidal role to be discussed later.

Many of the strongly cationic

granular proteins also seem to be microbicidal, perhaps by binding to
acidic groups on the target organisms and in some way preventing growth.
In addition, lactate accumulation and carbonic acid production result
in an acid environment in the phagocytic vacuole; this has an adverse
effect on most organisms, as well as promoting the reactions described
below.
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In the normal sequence of events phagocytosis is followed by
a burst of metabolic activity; the actual stimulus has been shown to
be mediated by surface perturbation [63,64].

The oxidation of glucose

via the hexose monophosphate shunt increases as does oxygen consumption,
setting into motion the oxygen dependent bacterial mechanisms.

Recent

evidence has shown that the first event in the formation of bactericidal
compounds is a one electron reduction, of oxygen, resulting in superoxide
anions, 0^

[65]

[Figure 2],

Not only is this agent intrinsically

toxic, but it is an intermediate in the production of more such agents,
^2^2 an<^

^ the following reactions:

(1)

2 0 • + 2H+ - H20? + 02

[66]

(2)

02" + H202 -> 02 + Oil” + OH*

[67]

These substances,

together with other unstable intermediates (for

example singlet oxygen) comprise the myeloperoxidase independent,
oxygen dependent bactericidal system.

In the myeloperoxidase mediated

system, hydrogen peroxide and an oxidizable cofactor, usually a halide,
are required.

The hydrogen peroxide, provided by bacterial or leukocyte

metabolism, forms a complex with the iron of the heme moiety delivered
into the phagocytic vacuole by degranulation; this complex in turn forms
antimicrobial substances by oxidizing the cofactor.

The nature and

mode of actions of these substances are known to vary with the cofactor
but are not completely understood [67],

Figure 2 demonstrates some of

the postulated interrelationships between phagocytosis-stimulated oxygen
consumption, superoxide and peroxide formation and pathways for their
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utilization in intact granulocytes.

NEUTROPHIL ABNORMALITIES

Disorders of Production and Delivery [5,8]
Neutrophil disorders can best be divided into those of production
and delivery, recognition and ingestion,

and killing and digestion.

Granulocytopenia, here defined as a reduction in circulating neutrophils,
can result from reduced granulopoiesis,
or decreased cell survival.

impaired release from the marrow,

A variety of drugs and infections can

produce granulocytopenia by any one or a combination of these mechanisms,
and several hereditary syndromes exist which have been tentatively
classified.

Infantile genetic agranulocytosis is among the examples

of reduced granulopoiesis.

Inherited in an autosomal recessive pattern,

the findings consist of marked neutropenia, moderate anemia, frequent
severe infections and a bone marrow revealing maturation arrest at the
myelocyte stage.
exist:

Two forms of an autosomal dominant familial neutropenia

one in which there is moderate neutropenia, no clinical diffi¬

culties, and an essentially normal bone marrow, and a more severe type
in which infections are very common and most of the granulocytes do not
mature beyond myelocytes.

An interesting report exists of two brothers

with periodontal and throat infections whose granulocytes showed this
maturation defect and whose plasma inhibited the differentiation of
normal cells.

A number of cases of cyclic neutropenia, involving

approximately three week cycles of neutropenia and mild infection, have
been described.

It seems likely that the problem is one of mild marrow
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failure and feedback mechanisms.

Schwachman's syndrome consists of

pancreatic insufficiency and neutropenia,
the degree of the latter.

the infections varying with

Neutropenia can also be associated with

immunoglobulin abnormalities, usually in the pediatric age group.
Bone marrow examination again reveals myelocyte arrest, and the patients
are subject to numerous infections.

In another type of neutropenia,

the entire granulocyte series is hypoplastic, in contrast to the normal
erythropoiesis and thrombocytopoiesis.
infections are apparent.

Classically, chronic dermatologic

Myelophthisis is another cause of reduced

granulopoiesis, although pancytopenia is more likely to develop.
Chronic benign neutropenia is believed to result from increased
peripheral destruction, and therefore belongs in the second category.
The bone marrow reveals bands but few mature forms, and most patients
have a moderately increased incidence of pyogenic infection.
but clinically less severe form exists in adults.

A similar

Two kinds of transient

neonatal neutropenia have been reported, one in which the mothers them¬
selves also were neutropenic and one, similar to red cell incompatibility,
in which the mothers presumably had become sensitized to the fetus'
leukocytes and transmitted agglutinins.

Cases of leukocyte autoantibody

and neutropenia often occur with connective tissue diseases, particularly
systemic lupus erythematosis.
granulocytosis,

The opposite of granulocytopenia,

can result from any one of a large number of conditions,

for instance infections, inflammatory disorders,

tumor, treatment with

certain drugs (e.g., corticosteroids), emotional stimuli, and metabolic
and hemotologic diseases.

Hereditary forms, although extremely rare.
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also exist.

A number of mechanisms including increased production of

cells in the marrow and release into the circulation shifts from marginating to circulating pools or decreased exit from the circulation
can be invoked to explain granulocytosis in these states.
The Pelger-Huet anomaly is an example of another type of
production disorder,

that of a predominantly morphologic abnormality.

It is a dominant condition which,

in the heterozygous state,

leukocyte nuclei to have a decreased number of lobes,
"pince-nez" nuclei.

causes

so called

That, together with the persistence of nucleoli

and the coarse nuclear chromatin, are suggestive of an abnormality of
nuclear maturation.

While these cells function normally,

zygous state is felt to be lethal.

the homo¬

Interestingly, similar cells are

seen in pseudo or acquired Pelger-Huet anomaly, which is associated
with various malignancies, metabolic diseases,

infections, and so forth.

A generally benign condition with hypersegmented nuclei is also known,
and can mimic the morphology seen in vitamin

or folate deficiency.

The May-Hegglin anomaly is a disease in which the granulocytes have
basophilic inclusions but apparently function normally; the platelets,
however, also have inclusions and sometimes abnormal bleeding occurs.
Alder-Reilly leukocytes, associated with polysaccharide disorders such
as Hunter’s and Hurler's syndromes, also contain giant granules but
function normally.

The Chediak-Higashi syndrome and other granule

abnormalities will be discussed as disorders of phagocytosis as they
have important functional significance.
The well-named lazy leukocyte syndrome exemplifies impaired
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neutrophil delivery; interestingly, both random movement and chemotaxis
are impaired.

This presumably causes the peripheral neutropenia and

poor response to infection.

Other tests of phagocytosis, bactericidal

capacity, and humoral and cellular immunity are normal.

The two children

with the disease had presented with recurrent stomatitis, otitis,
gingivitis, and low grade fevers

[68].

The constellation of findings known as Job's syndrome was first
described in two red haired, fair skinned girls with recurrent cold
staphylococcal abscesses [69],

Laboratory tests on these patients

[69,70] revealed no abnormalities, although two similar patients
reportedly failed to reduce nitroblue tetrazolium [71]
discussion of this test).

(see below for

More recently, however, a paper has appeared

in which the leukocytes were found to have defective chemotaxis and
extremely high IgE levels.

Random migration, phagocytosis and bac¬

tericidal activity against staphylococcus and JE. coli were normal.
The suggestion was made that patients with Job's syndrome lack the
ability to develop an early inflammatory response and are therefore
extremely susceptible to staphylococcus,
the skin.

the most common bacterium on

Some experimental support is available in animals,

in whom

it has been shown that infection will be suppressed only if an appropriate
inflammatory response takes place in two to four hours.

The authors'

explanation for the lack of classic signs of inflammation associated
with the abscesses was intriguing, although pure speculation:

the

leukocytes, spending more time in the systemic circulation and there
being exposed to an increased histamine level, might therefore release
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fewer inflammatory mediators in local sites

[72].

Clark et aJL.

[73]

reported a case of an eleven year old girl with recurrent pyogenic
and mucocutaneous Candida infections.

Examination revealed normal

production of chemotactic factors, but impaired migration; cellular
immunity also was abnormal.

One possible etiology of abnormal mobility

was suggested by a brief report of an infant with bacterial skin and
visceral infections, neutropenia, and decreased migration.

Electron

microscopy showed a defect of contractile proteins comprising cellular
microfilaments, perhaps of actin polymers [74],

Other factors may also

be involved; for example, cirrhotic patients have impaired chemotaxis
associated with both a serum inhibitor and a deficit of complement [75].

Disorders of Recognition and Ingestion [59]
Several examples of recognition and ingestion defects are known.
Defective opsonization may be partly responsible for the increased
susceptibility of newborns to infection.

IgM, which may be useful in

the opsonization of gram negative organisms,

is not transported across

the placenta and lack of it may account for some of this
of both IgG [77] and complement

[76].

Levels

[78] are related to birth weight, which

may lead to additional difficulties for low birth weight infants.

It

has been shown that serum from sickle cell patients does not enhance
pneumococcal phagocytosis as well as normal serum, and there is some
evidence that this is due to a defect in the alternate complement
pathway [79].

An infant with eczema, diarrhea, and recurrent infections

with staphylococci and gram negative organisms was reported to have
a dysfunction of C5.

Although no decrease in C5 could be found, the
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defect v/as repaired by the addition of purified C5

[62,80].

Defects

of other complement components, resulting in a wide range of clinical
findings, have also been reported [81].
termed tuftsin deficiency.
to leukokinin,

Another type of syndrome is

Tuftsin is a tetrapeptide covalently bound

a leukophilic gamma globulin.

It is cleaved off by

an enzyme called leukokininase and is thought to act directly on the
phagocyte, not the opsonized target.

Tuftsin is probably synthesized

in the spleen, as it is absent in splenectomized individuals.
patients with rash,

lymphadenopathy,

and pulmonary disease,

Four

caused by

staphylococcus, streptococcus, Candida, and perhaps other organisms,
have been reported.

They were found to have an inactive tuftsin mutant,

and clinically they responded to the administration of gamma globulin
[82].

Disorders of Killing and Digestion [59]

(See Figure 2)

Among the causes of impaired killing and digestion are disorders
which affect the neutrophil granules.

Chediak-Higashi syndrome appears

to result from abnormal granule formation in cells throughout the body,
but the primary defect is not known.

Histochemically,

the granules

contain normal constituents for the cell line in which they appear; in
neutrophils,

they are primary granules.

Patients with the disease have

light coloring, due to the decreased number of melanin granules,
an increased incidence of infection.

A study by Root et al.

and

[83] showed

that Chediak-Higashi neutrophils have defective bactericidal defences
against catalase positive and catalase negative organisms, secondary
to a delay and a decrease in the transfer of granule enzymes.

Phagocytosis
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as well as the metabolic response to phagocytosis were found to be
normal, but the authors note that neutropenia and an impaired chemotactic
response have also been demonstrated in this disease.

A second type

of primary granule abnormality is myeloperoxidase (MPO) deficiency.
As described above, MPO is required for part of the oxygen-dependent
bactericidal system of leukocytes.

It may also help regulate hexose

monophosphate shunt (HMP) metabolism, and help protect neutrophils from
the toxic effects of

[84],

In the presence of azide and cyanide,

which inhibit MPO by forming complexes with the iron in the heme moiety,
killing of Lactobacillus acidophilus,
t.ropicalis is impaired [85].

Staphylococcus aureus, and Candida

MPO deficiency, which appears to be an

autosomal recessive trait, has been described in five patients.

Of

these, only one had an increased susceptibility to infection; he had
disseminated candidiasis, but it should be noted that the patient had
diabetes mellitus as well.

Study of the neutrophils revealed normal

phagocytosis, decreased killing of serratia and S.
killing of Candida.

HowTever,

aureus, and absent

the fact that the man did not present

until middle age, and that the other cases are clinically wTell, speaks
against MPO being an essential part of defense mechanisms

[84].

Perhaps

the polymorphonuclear leukocytes have a great overkill capacity, or
perhaps they are able to compensate with an increase in their non MPO
dependent bactericidal mechanisms.
by Klebanoff’s

The latter suggestion is supported

[85] demonstration that MPO deficient leukocytes are

more efficientthan azide treated normal leukocytes in killing ingested
bacteria.

It is interesting that one case of anomalous specific,

.
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secondary granules has been reported.

A 14 year old boy with recurrent

staphylococcal infections of the skin and respiratory tract had neutro¬
phils with bilobed nuclei and decreased bactericidal activity against
staphylococcus.

A complete lack of leukocyte alkaline phosphatase was

found and may have been related in some way to the killing disorder
[86], although it should be noted that the low-leukocyte alkaline
phosphatase in chronic myelogenous leukemia is not associated specifi¬
cally with impaired microbicidal activity.
A second category of defective bactericidal mechanisms is that
in which the neutrophils do not have the appropriate metabolic response
after phagocytosis: they do not increase their oxygen consumption and
glucose metabolism to produce

.

While all aerobic bacteria produce

^2^2 ^ ^eir own metabolic pathways, some contain catalase to break it
down.

Catalase negative organisms, however, provide a source of

which is apparently sufficient to allow normal bactericidal mechanisms
to proceed; hence, patients with this sort of abnormality are more
prone to infection with catalase positive bacteria only [87].

The.

large number of reactions involved in hydrogen peroxide production and
catabolism implies that any one of a number of different enzymatic
defects could produce this picture (see Figure 2).

In chronic granu¬

lomatous disease, of childhood (CGD), perhaps the best known example
of this type of disease, recent work has shown a deficiency of NADPH
oxidase activity [87],

The function of this enzyme is to generate the

highly reactive reduction product of oxygen superoxide.

Hydrogen

peroxide is then formed by a dismutation reaction in which one molecule
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of

is oxidized and the other reduced producing

anc^ ^2*

defect in CGD is probably a failure of activation rather than an
absence of the enzyme [88],

Much of the earlier confusion may stem

from the fact this deficiency can be detected only in phagocytizing
cells, whereas resting cells appear normal.

The failure in pentose

shunt activity is believed to be secondary to the failure of
production.

Classically, these patients are males whose disease is

inherited in an X-linked recessive pattern.

Catalase positive bacteria

which are ingested, but usually not killed, are transported to the
reticuloendothelial system, where they gradually are released and
rephagocytized by macrophages which may be similarly defective [89].
The granuloma formation which follows can be compared to that of
tuberculosis and brucellosis, where live organisms also survive intracellularlv for long periods of time [90].

The typical clinical picture

is one of widespread reticuloendothelial involvement (lymphadenopathy,
hepatomegaly, splenomegaly) as well as numerous infections

(pustulur

dermatitis, conjunctivitis, osteomyelitis, subcutaneous abscesses,
pneumonia).

Laboratory workup should include a nitroblue tetrazolium

(NBT) test as part of an evaluation of immune competence.

Normal

leukocytes reduce this soluble yellow dye to an insoluble purple
formazan which is easily visualized [91].

CGD leukocytes, for reasons

probably related to decreased superoxide anion production [66], are
incapable of reducing the dye.

In a few instances, patients who appear

to have CGD have been found to lack glutathione peroxidase rather than
NADPH oxidase.

This has been noted mainly in females

[92], although

•

;
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one case of a Japanese male has been recorded [93].

CGD,

therefore,

may not be a single disease entity.
Glucose-6-phosphate dehydrogenase appears to be intimately
involved in hydrogen peroxide formation and catabolism.

Through the

activity of G6PD, the NADPII needed to reduce oxygen to superoxide is
produced.

Hydrogen peroxide is then derived from

as shown in Figure 2.

by dismutation

On this basis, one might predict that a lack of

leukocyte G6PD would cause a lack of hydrogen peroxide formation and
affect cellular metabolism and function in a way mimicking CGD.

A

comparison of the two types of cells has been made, and it was found
[94]

that leukocyte G6PD levels less than 5 percent of normal resulted

in defective killing of catalase positive bacteria.
leukocytes,

Similar to CGD

there is no post phagocytic respiratory burst with

production, and there is failure of NTjT reduction.

Both will reduce

NBT if cells are disrupted and NADH or NADPH is added.

The addition

of methylene blue (MB) differentiates the two types of cells by the
following reactions:

(1)

NADH/NADPH + MB

dlaPhora5e

,

NAD/NADP + MBH

(2)

MBH + 02 -S°S£°ma.tic„_., m + h2o2

MB added to CGD cells will stimulate normal pentose shunt activity and
improve microbicidal activity [94],

G6PD deficient cells which have

decreased levels of NADH and NADPH will exhibit no such response on
exposure to MB.

Further study of the G6PD deficient cells revealed

normal phagocytosis,

granule formation,

and degranulation.

Leukocytes

’

■

.

'
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with G6PD activity of 20-50 percent of normal had no functional defects;
as mentioned before, only at 1-5 percent levels were bactericidal
abnormalities detected [94],
One group of investigators

[95] postulated that G6PD deficiency

might be responsible for some cases of classic CGD; they observed an
increased rate of decay of G6PD activity in three male CGD patients.
A 16 month old girl with CGD, defined by a compatible clinical history
and failure to reduce NBT, was found to have a white cell G6PD level
approximately half of normal.
were first cousins [96].

Of note is the fact that her parents

While the clinical significance of these

reports can be questioned, at least two patients with complete absence
of leukocyte G6PD and impaired microbicidal activity are known.

One

was a middle-aged Caucasian female with hemolytic anemia and fatal
E. coli sepsis

[97],

Studies of her leukocytes, whose G6PD activity

was completely nondetectable, revealed normal bacterial ingestion,
normal destruction of S_.
destruction of S_.

faecalis (catalase-negative), and abnormal

aureus, _E.

coli and S_. marcesens

(catalase-positive).

As one would predict, an NBT test revealed no reduction.

Measurements

of leukocyte NADH and NADPH oxidase were not different from controls.
The patient’s post-transfusion erythrocyte G6PD level was 50 percent
of normal; four brothers,

three sisters and one son all had normal red

and white cell G6PD and no increased incidence of infection.

Genetically,

it is possible that the patient was homozygous for an autosomal recessive
gene which in some way affects G6PD activity, or that she was hetero¬
zygous for the X-linked G6PD gene.

In the latter case, one must invoke
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the Lyon hypothesis and postulate that most of the cells with the
normal gene were inactivated [97].
et al.

A family was described by Gray

[98] in which the male propositus had chronic nonspherocytic

hemolytic anemia, pneumonia, and recurrent granulomatous staphylococcal
infections since puberty.

Leukocyte function abnormalities were similar

to, although less marked than the previously described patient.

Roth

erythrocyte and leukocyte G6PB were nondetectable, even by immunologic
studies.

Of two brothers with the. same G6PD finding, one had had a

single episode of cervical lymph adenitis and one had no history of
unusual infections.

The father had low normal and the mother inter¬

mediate levels of red and white cell G6PD.
phagocytosis

(glucose oxidation,

Metabolic activity post

formate oxidation and iodination) was

nearly identical in the propositus and his brother with lymphadenitis;
these measurements were not made in the symptom-free brother, although
his leukocytes had not reduced NBT.

Conceivably two X-linked genetic

defects, G6PD deficiency and a form of CGD, are present in this family,
but it seems more likely that the G6PD deficiency is responsible for
the clinical symptomatology.
A disorder termed lipochrome histiocytosis bears some resemblance
to the disorders of bactericidal function just described and some feel
it is a type of CGD.

Three sisters with the syndrome have been reported,

of whom one failed to reduce NBT.
respiration and HMP activity.

All had impaired post phagocytic

Other clinical and laboratory features

included pulmonary infiltrates, splenomegaly, rheumatoid arthritis,
increased susceptibility to infection, hypergammaglobulinemia and

.

28

defective staphylococcal destruction; pathologically,
had lipochrome pigmentation.

Unlike CGD,

the histiocytes

there was no evidence of

granuloma formation, in spite of the bactericidal defect presumably
resulting in prolonged intracellular survival of bacteria

[99,100].

Miscellaneous Disorders
A number of other, for the most part, poorly understood syndromes
exist which have in common defective killing of staphylococci; some may
turn out to be the same as one of the above.

A female patient with

recurrent staphylococcal infections had normal chemotaxis, phagocytosis,
and NET reduction, but an unstable leukocyte pyruvate kinase.

Other

leukocyte enzymes, as well as red blood cell and lymphocyte pyruvate
kinase, were normal [101].

Another young woman with staphylococcal

facial infections, pneumonia and bacteremia was found to have normal
leukocyte bactericidal activity against E_. coli but defective activity
with staphylococcus.

The fact that the parents were related and that

there was a rather high number of infant deaths in the- family pedigree
led the author to suggest an autosomal recessive disorder, but its
nature is not known [102].

A girl with fatal phycomycosis whose

leukocytes showed decreased bactericidal capacity against staphylococcus
and a negative NBT test might have had a form of CGD, but her sex and
benign clinical course until the age of 13 is extremely atypical [103].
A family in which two, possibly three siblings of both sexes suffered
from oral, respiratory and skin infections has been reported; unlike
in CGD,

the neutrophils exhibited a normal respiratory burst with

phagocytosis of IgG coated particles, but not with plain latex particles
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[104],

Finally, it should be pointed out that not all of these syndromes

are necessarily related to neutrophil dysfunction.

A potential example

is a male with repeated staphylococcal infections culminating in death
at age 19.

Although his immunoglobulins were normal, he was found to

lack specific antibodies to the staphylococcal F and S antigens of
leukocidin.

The hypothesis was made that the patient may have become

tolerant of staphylococcal antigens during the second trimester of
pregnancy when his mother had impetigo [105].

Such speculation is

interesting but wild, and is perhaps an indication of the great amount
of work that remains in the field of host defense mechanisms.

Ill

Introduction
In the preceding section neutrophil function and dysfunction
were discussed, and the role of G6PD in bactericidal mechanisms reviewed
in the context of other abnormalities.

Leukocytes with a G6PD level

less than 5 percent of normal were shown to have defective killing of
catalase positive bacteria;

several cases of individuals with G6PD

deficient leukocytes and increased infection susceptibility were cited.
Other ways in which G6PD deficiency might be related to infection have
been proposed, for example, via the hemolysis which so often occurs.
Kaye and his collaborators

[106,107] have shown that acute hemolysis

in mice lowers resistance to S..
but not to D. pneumoniae.

typhimurium, E. coli, and JS. aureus,

They theorized that macrophages may become

temporarily overloaded with erythrocyte products, and may be unable to
sustain their usual bacterial defenses as well.

The possibility also

exists that free hemoglobin itself can increase infection susceptibility,
by providing an easily accessible source of iron for invading microbes
[108].

In addition, there is some evidence that G6PD deficiency is

associated with pneumococcal and salmonella infections, suggesting a
defect in opsonization'similar to that in sickle cell disease [A2].
That G6PD deficiency can adversely affect host defense against
bacterial infection in isolated individuals has been fairly well
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established as described above, but whether it also plays a role in
large populations is not known.

In order to answer this question, we

decided to study a population in which severe G6PD deficiency and
bacterial infections were both common,

to see whether infected patients

had a higher rate of G6PD deficiency.

Although it was not feasible

for us to measure leukocyte G6PD levels in addition to those in the
erythrocytes, we chose a Caucasian population in which deficiency of
the latter is known to be associated with deficiency of the former.
All bacterial infections were included, and where possible, subgroups
were analyzed, to allow for the different mechanisms that may be
operative.

Materials and Methods
(a)

Patient selection
The project was carried out in Shiraz, Iran at Nemazee and Saadi

Hospitals,

two teaching hospitals affiliated with Pahlavi University

Medical School.

All subjects were Iranian males, and all except one

were inpatients at one of these hospitals.

Approximately three times

per week charts were reviewed of all adult patients in Nemazee Hospital,
and from the medical, orthopedic and neurosurgical wards in Saadi
Hospital.

During the last month of the three month period, pediatric

charts were also reviewed.
and when necessary,

Patient data were gathered from the charts

from responsible medical personnel.

The data

collected included age, place of origin, history of present illness,
past medical history, family history, physical examination findings,
laboratory data, procedures performed, therapy received, and hospital

'■
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course.

All male inpatients with bacterial infections and no known

predisposing reason to infection other than possible G6PD deficiency
were studied as the infected group.
or more of the following methods:
diagnostic taps,

Infections were diagnosed by one
cultures, titers, biopsies, x-rays,

and antibiotic response.

In cases where the etiologic

agent was definitively established by cultures,
the patient was categorized as Class I.

titers, or biopsies,

In other cases the presence

of a bacterial infection was well established by a combination of
clinical symptoms, x-rays, examination of body fluids, biopsies and
antibiotic response, but proof of the etiologic agent was not obtained
and the patient was categorized as Class II.

Patients in whom an

etiologic agent was highly suspected, but not proven (for example,
a chest x-ray with cavitary lesions in a person with clinical signs
of tuberculosis) wrere also placed in the latter category.

The one

outpatient in the infected group was seen at Nemazee Outpatient Clinic,
brucellosis titers were diagnostic, and it was elected to give him
antibiotics at home rather than in the hospital.

Those patients free

of diseases known to be associated with infection or G6PD deficiency
were selected as control "A".
systemic diseases were avoided.

As far as possible, all individuals with
Thus,

to isolate G6PD deficiency as

a potential cause for bacterial infections, patients who had the
following conditions or treatments were, excluded from the infected and
the major control groups:

steroid therapy, malignancy, diabetes

mellitus, cirrhosis, chronic renal or cardiac failure, sickle cell
anemia, Cooley’s anemia, malaria, hydatid cyst, open trauma, opium
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^buse, viral infections,

tetanus, vasculitis or renal stones, and those

in whom no diagnosis could be made.

Most patients identified with these

conditions were not tested, since these disorders in and of themselves
can predispose to secondary bacterial infections.

In some situations

G6PD testing was performed on individuals with these conditions before
all clinical data was available, and they serve as control "E".

This

provided us with two control groups; control "A" is a group selected
for a lack of predisposing factors for bacterial infection, and control
"B" a group with a variety of potentially predisposing factors to
infection, or syndromes which mimicked bacterial infections in some
of their features.

(b)

Assay
Measurement of erythrocyte G6PD activity was carried out as

follows:

for each assay approximately 5 cc. of blood was drawn into

a syringe, transferred immediately to a Vacutainer tube containing EDTA,
and mixed well.

Bloods were refrigerated at 4°C within 15 minutes and

were tested within three days with the semiquantitative method developed
by Sigma (Technical Bulletin No. 400).

Kit instructions were followed

exactly, including appropriate compensation for the degree of anemia
present.
G6PD,

In this assay, erythrocytes are lysed by water to release

This solution is then added to glucose-6-phosphate and NADP in

the presence of phenazine methosulfate, an electron carrier and
dicblorophenol indophenol, a blue dye.

The NADPH formed during the

oxidation of glucose-6-phosphate to 6-phosphogIuconate reduces the dye
to a colorless form, and the rate of the reaction can be followed
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visually.

The tubes are observed for a six hour period.

For a

minority of patients the quantitative test for G6PD activity performed
in the Nemazee Hospital Laboratory (Brilliant Cresyl Blue Reduction,
Dade, Miami, California) was used.

In these cases, only samples with

0% activity were considered deficient.

(c)

Grouping of data and statistical analysis
Statistical significance of differences in rates of G6PD defi¬

ciency were determined by the chi-square method of 'analysis.

Infected

patients were compared with control "A" and control "A" plus control "B"
No separate comparisons with control nB': were made, because of the
small number of subjects.

Subgroups of patients matched exactly for

age and origin were analyzed in a similar way.

Those infected patients

in whom an etiologic agent was established were divided according to
whether the agent was catalase positive or negative.

The catalase

positive group was compared with controls, but the catalase negative
group was too small to permit statistical analysis.

The unpaired "t11

test was used to analyze the mean age difference between the G6PD normal
and the G6PD deficient infected groups.
the unpaired "t" test, p <

With both the chi-square and

.05 is considered statistically significant.

Results
(a)

Assay validity
Before conducting the studies in Iran assays were run at Yale

University School of Medicine using blood samples tested quantitatively
by the Yale-New Haven Hospital laboratories.

The age of the samples
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ranged from two hours to eleven days.

Samples of all ages with normal

G6PD activity decolorized within one hour, and samples with 10 percent
activity decolorized in two to two and a half hours,

consistent with

data obtained by Sigma.
In Iran, an effort was made to study all infected patients as
soon as possible after admission, usually within a few days.

It was

not always feasible to carry out the assays when no medications were
being given; however, a complete list of drugs that each patient was
receiving was compiled, and no agents that might have affected the assay
were present in the study group.

Fourteen of our seventeen abnormal

samples had not decolorized at 6 hours, indicating very severe defi¬
ciency.

Two of the remaining three took 3 hours but when repeated

took 4 hours or more, and the third took 4^ hours but could not be
repeated.

Of the 14 that took more than 6 hours,

5 were randomly

repeated and all confirmed the original result; in 2 cases the assay
was performed within 2 hours of the time the blood was drawn.

Three

of the normal assays were repeated and confirmed.

(b)

Patient characteristics
The demographic characteristics of all patients are presented in

Table 3.

The average age of the 55 infected patients was 31 years;

the

G6PD normal group differed substantially from the G6PT) deficient grouD,
34 years compared to 22.
(.005 > p >

.001).

age of 34 years,
38 years.

This difference was statistically significant

There were 65 control "A" patients, with an average

and 33 control "B" patients, with an average age of

In these two groups there was no marked difference between

.
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G6PD normal and G6PD deficient patients.

The distribution between

those from villages and from major cities was relatively even, although
a somewhat greater proportion of the control "A" group came from the
cities.

Of the city patients, a total of seven came from places other

than Shiraz (three infected patients and three control "B,: patients,
one each from Yazd, Teheran, and Mashad, and one control "A" patient
from Yazd).

It seems reasonable to assume that villagers are less

likely to travel,

and that therefore an even smaller percentage is

from outside the Shiraz area.
The criteria by which infections were established are listed
in Table 4, and the diagnoses themselves in Table 5.

Tables 6a and 6b

contain the diagnoses of control "A" and control "B" respectively.
Some of the patients had a history of a disease other than that for
which they were admitted to the hospital.

Of the infected patients,

three had a past history of typhoid (the present illnesses were two
with pneumonia and one with osteomyelitis), one had psoriasis
losis), and one had hypertension (meningitis).

(shigel¬

Of the control "A”

patients, one had had typhoid (snake bite), one had had malaria (upper
gastrointestinal tract bleed), and one had an ulcer (low back pain);
of control "B:l patients, one had rheumatoid arthritis (and was on
steroid therapy) and one had had smallpox (diagnosis of present illness
not made).
The results of the G6PD assays are in Table 7.

Twenty two

percent of the infected patients were G6PD deficient, compared to
twelve percent of control "A" and six percent of control "B" (Table 7a).
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Tables 7b,

7c, and 7d show the rates of G6PD deficiency in three sub¬

groups, one with matched ages, one with matched origins (villagers
only), and one selected on the basis of whether the etiologic agent
was catalase positive or catalase negative.
important from two aspects:

Matching for age wTas

older patients might have a lower frequency

of G6PD deficiency if the gene causes an increase in mortality rates
and older patients have a naturally higher rate of infection for a
variety of reasons.

Matching for origin was important to account for

genetic differences in rates of G6PD deficiency, and genetic and environ¬
mental differences in rates of infection.

We looked at whether infections

were caused by catalase positive or catalase negative organisms, because
of the previously cited work showing the G6PD deficient leukocytes may
be similar to CGD leukocytes in demonstrating impaired killing of cata¬
lase positive organisms [92],
For Tables 7a,

7b,

and 7c the differences in rates of G6PD defi¬

ciency between the infected group and control "A11 were analyzed by the
chi-square method, and in all cases the differences were found not to
be statistically significant

(p > .10).

Comparisons were also made

between each infected group and control "A" plus control "B".

The

results are as follows:

Table
7a
7b
7c

Patient Group
all
age-matched
origin-matched

X^

£

3.86
3.67
1.79

.05 > p > .01
.10 > P > .05
P ~ .10

Thus, when controls "A" and "B" together are considered as the control
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group,

the differences in rates of G6PD deficiency reached statistical

significance.

No separate comparisons with control "B" were made,

owing to the small number of subjects.

For Table 7d,

the catalase

positive group was compared with all control "A" patients

(Table 7a),

and with all control "A" patients plus control "B" patients

(Table 7a).

The differences were not statistically significant (p > .10).

The

catalase negative group had no G6PD deficiency, but statistical analysis
was not carried out because of the small size of the group.
Mortality data was collected but is incomplete because it was
not possible to follow patients remaining in hospital after termination
of the study.

As far as is known, none of the 12 G6PD deficient infected

patients and 2 of the 43 G6PD normal infected patients expired.

There

was no mortality in the control ’’A" group of 65 patients; in control "B11,
one of the 2 G6PD deficient and 3 of the 31 G6PD normal patients failed,
to survive.

Discussion
The frequency of G6PD deficiency in Iran has been studied by
a number of other investigators
rough agreement.

(see Table 8), and our results are in

We did not have enough geographic distribution to

confirm or refute Beaconsfield1s

[110]

finding of a higher incidence

in previously malaria-infested areas.
Although the rates of G6PD deficiency were greater in infected
than in control groups,

the differences were not significant when the

control group was matched as closely as possible for age, origin, and
underlying diseases.

When we included a secondary control group with
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a variety of conditions that were not present in the infected groups,
the differences reached significance (p as low as .05 > p >
patients matched exactly for age).

However,

.01, in

the secondary control

group included patients whose susceptibility to infection might have
been increased due to disease (other than G6PD deficiency) or therapy,
thus it was not strictly comparable with the infected patient group.
One might expect an artificially low rate of G6PD deficiency in control
"B" as the combination of G6PD deficiency and infection could lead to
an increased mortality.

The same bias could occur if patients with

G6PD deficiency are less liable to develop the types of disorders
present in control "3".

Either of these possibilities would explain

why the differences in rate of G6PD deficiency between the infected
and control groups increase when the secondary control group is included.
Some studies have shown that G6PD deficient individuals are more
susceptible only to catalase positive organisms

(see previous section),

but our comparison of the group infected with catalase positive
organisms and the controls showed no statistically significant differ¬
ences in the frequency of G6PD deficiency.

Although the rate of G6PD

deficiency in the catalase negative group was zero,

the number of cases

was too small to permit meaningful statistical analysis.

Neither did

we have enough subjects with any one disease to analyze separately,
and so we cannot make a definite statement on this issue.

However,

the G6PD deficient patients did seem to have a disproportionate share
of staphylococcal septicemia, pneumonia, and brucellosis.

We also

compared the demographic characteristics of the G6PD deficient infected
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group with the G6PD normal infected group.

The average age of the

former was 22 years, and the latter 34 years
at the .005 > p >

.001 level).

(difference significant

One interpretation of this observation

is that the combination of G6PD deficiency and infection leads to
hospitalization at an earlier age than infection alone.

This is

consistent with the hypothesis that G6PD deficient patients, once
infected, have a more severe clinical course.

Data on mortality rates

would be useful in further testing of this hypothesis, but our data
are insufficient for this purpose.
It is important to point out what we feel are some potential
weaknesses in our study.

The number of patients sampled was relatively

small, and conceivably some of the observed trends might become signifi¬
cant only in a large population study.

Lack of optimal facilities and

culturing techniques prevented us from establishing every diagnosis of
infectious disease by culture, and sampling error might have been involved
in those that were.

It was not possible for us to fully document

previous antibiotic therapy, and this would be important in altering
the course of infectious diseases.

We were not able to measure leuko¬

cyte G6PD levels, which would have made our study more precise.

Exact

data on leukocyte G6PD activity would be particularly relevant in
establishing the clinical significance of defective pentose phosphate
metabolism in the cells.

Finally, the method of patient selection might

be faulted in several ways.

Specifically, ongoing hemolysis caused by

infection or its treatment can lead to hospital admissions.

By concen¬

trating only on patients with infections severe enough to result in

hospitalization, a true picture of a population's susceptibility to
infection is not obtained.

Rather, one has only an estimate of the

prevalence of serious infections, and this estimate does not differ¬
entiate between infections made more severe by G6PD deficiency (with
or without hemolysis)

and the reverse.

Close monitoring of hemolytic

parameters before hospitalization would be required to determine whether
this is a source of bias,

as well as perhaps producing information cn

the relationship of hemolysis and infection; it would also provide a
more accurate index of the incidence of infection in normal and G6PD
deficient subjects.

By selecting mainly adult patients, we automatically

minimized the chances of detecting very serious effects of G6PD defi¬
ciency on host resistance, which could result in early mortality.

Borne

of the information we attempted to collect may not have been reliable
and complete.

Thorough medical records were not always available and

some relevant data may have been deleted including precise statements
concerning ethnic background, nutritional status, and means of referral.
Another population study of the relationship of G6PD deficiency
and infection has been published by Lampe et al.

[42],

They compared

rates of G6PL) deficiency in hospitalized Thai children with S.

typhi,

H. influenza b, pneumococcus, staphylococcus, and tuberculous infections
with outpatient controls.

Taking only male patients, their data show

a difference in rate of G6PD deficiency between the infected group and
the controls approaching significance (p to ours.

.05), a finding rather similar

Their criteria for diagnosis of infectious disease were more

rigorous than ours, but their definition of G6PD deficiency is vague,

i-J

■
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and it is not clear how well the patients and controls were matched
for exact age and origin.

Furthermore, like our study,

their method

of patient selection precludes an estimate of the relative incidence
rates for infection in normal and G6PD deficient subjects.
Thus, while we can offer no final conclusions regarding the
relationship of G6PD deficiency and bacterial infections, a reasonable
interpretation of data from these studies is that the two conditions
do have meaningful interactions.

This statement is justified by our

data showing the G6PD deficient infected group to be significantly
younger than the G6PD normal infected group, indicating the adverse
effect of having both G6PD deficiency and infection.

Although a rise

in the rate of G6PD deficiency in an infected hospital population versus
a non-infected population was demonstrated both by Lampe and ourselves,
this rise approaches statistical significance only under certain cir¬
cumstances.

Therefore, whether it is real remains to be evaluated.

There are several mechanisms which would explain an association
between G6PD deficiency and bacterial infection.

First, as we have

suggested above, the oxidant stress of infection or its treatment may
lead to hemolysis and a weakening of host defenses against infection
as well as hospitalization.

Second, if the leukocyte G6PD level is

less than 5 percent of normal, bactericidal activity against catalase
positive organisms can be impaired.

On the basis of published information,

it is more likely that this occurs on an individual basis, rather than
in all patients with reduced leukocyte G6FD.

A thorough prospective

analysis of large groups Is required to pick up the more subtle
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influences which might increase infection rates as well as severity.
In such a study, the importance of other factors, such as hemolysis
and abnormal opsonization, could be evaluated.

This project would be

potentially useful in providing additional knowledge of host defense
mechanisms, as well as having clinical importance to the millio-ns of
people with G6PD deficiency.
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TABLE 2 (from Reference 1)
COMPOUNDS KNOWN TO HAVE INDUCED HEMOLYSIS OF
GLUCOSE-6-PHOSPHATE DEHYDROGENASE-DEFICIENT RED CELLS

Analgesics:
Acetanilid
Acetylsalicylic acid*
Acetophenetidin (phenacetin)*
Antipyrine
Pyramidone
Sulfonamides and sulfones:
Sulfanilamide
Sulfapyridine
Diaphenylsulfone
N2*-Acetylsulf anilamide
Sulfacetamide
Sulfisoxazole (Gantrisin)*
Thiazolsulfone
Salicylazosulfapyridine (Azulfadine)
Sulfoxone*
Sulfamethoxypyridazine (Kynex)
Antimalarials:
Primaquine
Pamaquine
Pentaquine
Quinocide
Ouinacrine (Atabrine)
Nonsulfonamide antibacterial agents:
Furazolidone
Furmethonol
Nitrofurantoin (Furadantin)
Nitrofurazone
Chloramphenicol £
Paraaminosalicylic acid
Neoarsphenamine
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TABLE 2 (continued)

Miscellaneous:
Naphthalene
Trinitrotoluene
Methylene blue*
Nalidixic acid
Dimercaprol (BAL)*
Phenylhydrazine
Ouininet
Quinidinet
Mestranol

* Slightly hemolytic in Negroes, or only in very large doses,
t Hemolytic in Caucasians, but not in Negroes.
£ Possibly hemolytic in Caucasians, but not in Negroes or Orientals.
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TABLE 4
DIAGNOSTIC CRITERIA IN INFECTED PATIENTS

CLASS

DIAGNOSIS
Pneumococcus
Staphylococcal sepsis
Streptococcal meningitis
Shigellosis
Anthrax
Brucellosis
Typhoid
Tuberculosis
A. israelii abscess

CLASS II:

CRITERION FOR DIAGNOSIS
Culture
Culture
Culture
Culture
Culture
Titer
Titer
Biopsy
Biopsy

DIAGNOSIS

CRITERIA FOR DIAGNOSIS1

Pneumonia
Meningitis
Osteomyelitis
Tuberculosis
Erysipelas
Brain abscess
Pyopneumothorax

CXR and response to antibiotics
LP and response to antibiotics
X-ray or biopsy
CXR
Response to antibiotics
Pus and air in CSF
Pus in pleural fluid

In all cases, clinical symptoms were also compatible.
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TABLE 5
LIST OF INFECTED PATIENTS BY DIAGNOSIS

Diagnosis

Osteomyelitis
Tuberculosis
Pneumonia1
Brucellosis
Staphylococcal septicemia
Meningitis2
Typhoid
Anthrax
Shigellosis
Erysipelas
Pyelonephritis
Pyopneumothorax
Brain abscess
Extradural abscess

Number of
Patients

12

Number
Deficient

2

9

1

8

A

6

2

3
3
3
3
3
1
1

1
1
1

2
1
0
0
0
0
0
0
0
0
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12

^In 2 cases, one of which was G6PD deficient, the etiologic agent
was determined by culture to be pneumococcus.

2

In 1 case, which was G6PD normal, the etiologic agent was deter¬
mined by culture to be 3hemolytic streptococcus.
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TABLE 6a
LIST OF CONTROL "A" PATIENTS BY DIAGNOSIS

DIAGNOSIS

Closed trauma
UGI bleed1
Disc herniation
Low back pain
Hernia
Minor congenital defect
Snake bite
Poisoning
Myocardial infarction
Burn contracture

Malignancy ruled out.

Number of
Patients

Number
Deficient

25

4

11

0

10
4
3
3
3
3
2

2
1
0
0
1
0
0

1

0

65

8
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TABLE 6b
LIST OF CONTROL "B" PATIENTS BY DIAGNOSIS

DIAGNOSIS

Malignancy
Pneumonia1
No diagnosis
Viral infection
Steroid therapy2
Open trauma
Diabetes mellitis
Cooley's anemia
Sickle cell anemia
CRF
CHF
Cirrhosis
Rheumatic heart disease
Tetanus
Renal stones
Opium abuse

Number of
Patients

Number
Deficient

6

1

4
4
3
3
2
2
1

1
0
0
0
0
0
0

1

0

1
1
1
1
1
1
1

0
0
0
0
0
0
0

33

2

^Underlying causes (malignancy, hydatid cyst, TB) not ruled out.

2

For rheumatoid arthritis, vasculitis unknown etiology, and
Henoch-Schonlein purpura.
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